BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline

April 13, 2017

Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strategy and R&D goals outside of oncology. Zioncheck discusses Genentech's multiple sclerosis and Alzheimer's portfolios, therapy areas not as widely promoted as the company's active and expansive immuno-oncology pipeline. Genentech's BD head also highlights the company's early-stage development program for a novel amyotrophic lateral sclerosis (ALS) therapy, a disease that has garnered more attention since the widely-shared ALS Ice Bucket Challenge—a social media fundraising and awareness campaign. The company is developing RG6000, a dual leucine zipper kinase (DLK) inhibitor, for the treatment of ALS. The drug, a new molecular entity, is currently in Phase I trials.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Article
Bruce Levine is a man you can thank for your future cell therapy
Bruce Levine is a man you can thank for your future cell therapy

To call Bruce Levine, PhD, an innovator in the cell and gene therapy space is a gross understatement. He is...

Next Video
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice

Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug d...